Navigation Links
Sinovac Files Annual Report on Form 20-F
Date:4/30/2013

BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccine products in China, announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2012 on April 30, 2013.  The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.

The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge.  Requests for a hard copy of the 2012 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form.

About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program.  Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, varicella and rubella.  Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac was also granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contact:
Helen Yang / Chris Lee
Sinovac Biotech Ltd. 
Tel:  +86-10-8279-9659/ 9696
Fax:  +86-10-6296-6910 
Email: ir@sinovac.com

Investors 
Stephanie Carrington 
The Ruth Group 
Tel: +1-646-536-7017 
Email: scarrington@theruthgroup.com

Media 
Victoria Aguiar 
The Ruth Group 
Tel: +1-646-536-7013 
Email: vaguiar@theruthgroup.com 


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
3. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
4. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
5. Sinovac Holds 2012 Annual General Meeting of Shareholders
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
8. Sinovac Schedules 2012 Annual Meeting of Shareholders
9. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
10. Sinovac Reports Unaudited First Quarter 2012 Financial Results
11. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of ... successfully concluded its meeting with the U.S. Food and ... insulin formulation. At ... regulatory pathway for submission of ORMD-0801, would be a ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/29/2017)... 2017 In a move that promises to ... for veterinary practices of all sizes, Cubex LLC and ... makes TITAN,s expertise in physical security, drug diversion investigations, ... nationally. "Every ... substances is at risk today," said TITAN founder and ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):